

A PROGRAM of the CANCER SUPPORT COMMUNITY

Multiple Myeloma Patient Experience with Financial Toxicity

Findings from the Cancer Experience Registry

Joanne S. Buzaglo, PhD Senior Vice President





American Society for Hematology 57th Annual Meeting, December 7, 2015

Background

- In the context of rising costs of health care, patients are having to assume more costs
- Patients have to assume both direct (co-pays, Rx) and indirect (transportation, loss of income) costs
- People living with MM may have to manage a significant financial burden related to care
- Financial toxicity is associated with reduced quality of life and poorer health outcomes
- Aim: To describe financial distress among MM patients and communication about cost of care with health care team.





- Tracks the social and emotional experience of cancer patients and survivors across the US
- Engages them to share their voices about issues that matter to them
- Provides a dynamic learning environment for patients, researchers, and other key stakeholders
- Connects an expanding number of registries












The Evolving Registry







Methods

- From July 2013-July 2014, a total of 266 US-based registrants completed survey questions:
 - Financial burden of MM and its treatment
 - 27 cancer-related distress items (0 "not at all" to 4 "very seriously concerned")
 - 4-item depression subscale (≥5 at risk for depression)
 - Stress-related thoughts about managing the financial impact of MM measured using the Impact of Event Scale
 - Communication about cost with health care team
- Descriptive and regression analyses



Sample characteristics (n=266)

Median age	64 years
Female gender	52%
Race White Black	91% 7%
Income <\$40	35%
Education At least college degree	58%
Median time since dx	4.5 years




Patient monthly out-of-pocket costs for MM







Due to the medical costs of MM





High emotional burden is associated with financial toxicity

- 47% were moderately, seriously or very seriously concerned about health insurance or money worries
- 33% reported they were often or always upset about money and the cost of care
- 32% of participants report experiencing clinically significant stress-related anxiety (intrusive ideation) about the financial cost of MM and its treatment



Increased out-of-pocket expenses are associated with greater distress

Monthly out-of- pocket costs	n	Risk for depression	Mean overall distress score
\$0-50	27	23%	26.1
\$50-100	43	33%	28.3
\$100-250	64	45%	32.7
\$250-500	68	49%	36.3
\$500-1000	36	50%	35.5
\$1000+	21	29%	29.4

Financial burden is associated with distress


Financial burden*		Risk for depression	Mean overall distress score
Yes	95	58%	40.6
No	171	33%	27.7

- Patients experiencing financial burden are 2 1/2 times more likely to be at risk for depression, holding income constant [OR comparing financial burden and risk for depression is 2.56 (95% CI 1.48, 4.4)]
- *Financial burden is defined as having depleted savings or borrowed against or used money from retirement.

Patients want financial counseling

- Only 28% reported their health care team discussed the impact of MM on personal finances.
- Yet, 82% reported financial counseling would be "quite a bit" or "very much" helpful to someone with MM

Patients are willing to get financial assistance



Conclusions

- People with MM are making significant lifestyle trade-offs in order to manage the cost of health care
- A significant proportion of patients are experiencing significant levels of emotional burden related to financial toxicity
- People with financial burden are almost two and a half times more likely to be at risk for depression compared to those without financial burden
- Patients want financial counseling and are willing to get help
- We need to ensure that patients have access to appropriate financial counseling and emotional/social support and that these services are adequately reimbursed and available in the community

Thank you

Melissa F. Miller, PhD, MPH Clare Karten, MS Margaret Longacre, PhD Victoria Kennedy, MSW Thomas LeBlanc, MD, MA

Sponsors

Amgen
Celgene Corporation

Any questions or comments

joanne@cancersupportcommunity.org